Propanc Biopharma (PPCB) Cash from Operations (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Cash from Operations of 999140.0 for Q4 2025, down 5434.72% year-over-year from 18729.0 in Q4 2024, and up 48.47% quarter-over-quarter from 1939067.0 in Q3 2025.
Propanc Biopharma (PPCB) Cash from Operations (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Cash from Operations for 15 consecutive years, with 999140.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations fell 5434.72% year-over-year to 999140.0; the TTM figure through Dec 2025 stood at 3126589.0 (down 439.47% YoY), while the FY2025 annual figure was 405168.0, up 56.67% from the prior year.
- Cash from Operations rose to 999140.0 in Q4 2025 per PPCB's latest filing, from 1939067.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 18729.0 in Q4 2024 and bottomed at 1939067.0 in Q3 2025.
- Historically, Cash from Operations has averaged 376216.85 across 5 years, with a median of 237586.0 in 2021.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 107.84% — and 2025, when it plunged 5434.72%.
- Propanc Biopharma's Cash from Operations stood at 224335.0 in 2021, then slipped by 0.4% to 225227.0 in 2022, then retreated by 6.06% to 238885.0 in 2023, then soared by 107.84% to 18729.0 in 2024, then slumped by 5434.72% to 999140.0 in 2025.
- Business Quant data shows PPCB's Cash from Operations at 999140.0 in Q4 2025, 1939067.0 in Q3 2025, and 27186.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -999,140.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -999,140.00 |
| Dec 31, 2025 | -999,140.00 |
| Sep 30, 2025 | -1.94 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -27,186.00 |
| Jun 30, 2025 | -27,186.00 |
| Mar 31, 2025 | -161,196.00 |
| Mar 31, 2025 | -161,196.00 |
| Dec 31, 2024 | 18,729.00 |
| Dec 31, 2024 | 18,729.00 |
| Sep 30, 2024 | -235,515.00 |
| Sep 30, 2024 | -235,515.00 |
| Jun 30, 2024 | -259,966.00 |
| Jun 30, 2024 | -259,966.00 |
| Mar 31, 2024 | -102,810.00 |
| Mar 31, 2024 | -102,810.00 |
| Dec 31, 2023 | -238,885.00 |
| Dec 31, 2023 | -238,885.00 |
| Sep 30, 2023 | -333,457.00 |
| Sep 30, 2023 | -333,457.00 |